<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ringold, Sarah</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New ACR Recommendations for Treating Juvenile Idiopathic Arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents a summary of the 2013 update to the 2011 American College of Rheumatology (ACR) treatment recommendations for systemic juvenile idiopathic arthritis (sJIA) [Ringold S et al. Arthritis Rheum 2013]. The purpose of the update was to expand the clinical scenarios for sJIA, to include recent data regarding the efficacy of the interleukin (IL)-1 and IL-6 inhibitors, to include macrophage activation syndrome, and to update the recommendations for follow-up tuberculosis screening for children receiving biologics.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>